Pseudovirus Nanoparticles Displaying the Receptor-Binding Glycoprotein of Marburg Virus as Potential Vaccine Candidates
Pathogens · 2026
DOI: 10.3390/pathogens15101087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2026. Verfasst von Ming Xia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. Hauptthemen laut MEDLINE: Marburgvirus, Nanoparticles, Viral Vaccines, Viral Envelope Proteins. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
The lack of a licensed vaccine against the deadly Marburg virus (MARV) calls for the development of a novel and effective vaccine strategy.
Methods
We report here our development of three pseudovirus nanoparticles (PVNPs), each displaying a MARV-neutralizing glycoprotein (GP) segment of different lengths, as MARV vaccine candidates. These PVNPs, designated S-GP278, S-GP377, and S-GP486, were generated using our proprietary norovirus shell nanoparticle (SNP) platform. The PVNPs were evaluated for their production, self-assembly, morphology, structural properties, and immunogenicity.
Results
Our data demonstrated that the three recombinant S-GP proteins, S-GP278, S-GP377, and S-GP486, can be produced at low cost using an E. coli expression system. The purified recombinant S-GP proteins self-assembled into PVNPs with high efficacy. Structural modeling of the S-GP1 PVNPs highlighted their key architectural features, consisting of an icosahedral inner shell and multiple trimeric GP structures displayed on the surface. Immunization of mice with the S-GP PVNPs elicited high titers of GP-specific antibodies, including IgG and IgA.
Conclusions
Collectively, these data support the notion that the S-GP PVNPs may serve as potential MARV vaccine candidates worthy of further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
- Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases
Zitieren
APA
Xia, M., Vago, F. S., & Tan, M. (2026). Pseudovirus Nanoparticles Displaying the Receptor-Binding Glycoprotein of Marburg Virus as Potential Vaccine Candidates. Pathogens. https://doi.org/10.3390/pathogens15101087
Vancouver
Xia M, Vago FS, Tan M. Pseudovirus Nanoparticles Displaying the Receptor-Binding Glycoprotein of Marburg Virus as Potential Vaccine Candidates. Pathogens. 2026. doi:10.3390/pathogens15101087
BibTeX
@article{Xia2026,
author = {Xia, Ming and Vago, Frank S and Tan, Ming},
title = {Pseudovirus Nanoparticles Displaying the Receptor-Binding Glycoprotein of Marburg Virus as Potential Vaccine Candidates},
journal = {Pathogens},
year = {2026},
doi = {10.3390/pathogens15101087}
}
EUVIMED